{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:56:51Z","timestamp":1794621411163,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Genetic studies in Latin America have expanded, but further efforts are needed to understand cancer susceptibility genes beyond <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic>, especially by characterizing the prevalence and spectrum of pathogenic or likely pathogenic variants (PVs) in the region. This study aimed to determine the frequency of hereditary cancer syndromes (HCS) in Colombians with solid tumors and to characterize the spectrum of PVs. Using data from the Colombia\u2019s largest Institutional Hereditary Cancer Program, we included patients aged \u226518 years with solid tumors who met HCS criteria and were offered genetic testing with a 105-cancer gene panel. We calculated the prevalence of PVs and HCS by cancer type (beyond breast) and gene. For patients with breast cancer, we examined genotype-phenotype correlations with molecular subtypes and stratified positivity rates by different genetic testing criteria. Among 769 patients, we identified 216 PVs in 43 genes in 197 patients (26%). Thirty-three PVs were recurrent. Autosomal HCS was found in 21% (160\/769) of patients (159 dominant, one recessive), while 5% (37\/769) were heterozygous carriers of PVs in autosomal recessive genes. In 42% (321\/769) of the cases, only one or more variants of uncertain significance (VUS) were identified, whereas 33% (251\/769) had neither PVs nor VUS detected (negative results). HCS prevalence varied by cancer type (11\u201326%). The triple-negative subtype and bilateral presentation were strong predictors of inherited breast cancer. Our study reveals a significant presence of PVs among high-risk Colombian patients with solid tumors, underscoring the importance of genetic counseling and testing in the region.<\/jats:p>","DOI":"10.1038\/s41431-025-01807-y","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T14:48:56Z","timestamp":1741618136000},"page":"913-929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Building a hereditary cancer program in Colombia: analysis of germline pathogenic and likely pathogenic variants spectrum in a high-risk cohort"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7946-2026","authenticated-orcid":false,"given":"Mar\u00eda Carolina","family":"Sanabria-Salas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Luc\u00eda","family":"Rivera-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carolina","family":"Manotas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4739-5260","authenticated-orcid":false,"given":"Ana Milena","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Tapiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Huertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Zamir","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Ria\u00f1o-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Parra-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Mej\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-2918","authenticated-orcid":false,"given":"Luis G.","family":"Carvajal-Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"1807_CR1","doi-asserted-by":"publisher","unstructured":"Nagy R, Sweet K, Eng C Highly penetrant hereditary cancer syndromes. Oncogene. 2004; https:\/\/doi.org\/10.1038\/sj.onc.1207714.","DOI":"10.1038\/sj.onc.1207714"},{"key":"1807_CR2","doi-asserted-by":"publisher","unstructured":"Mantilla WA, Sanabria-Salas MC, Baldion AM, Sua LF, Gonzalez DM, Lema M NGS in Lung, Breast, and Unknown Primary Cancer in Colombia: A Multidisciplinary Consensus on Challenges and Opportunities. JCO Glob Oncol. 2021; https:\/\/doi.org\/10.1200\/GO.21.00046.","DOI":"10.1200\/GO.21.00046"},{"key":"1807_CR3","doi-asserted-by":"publisher","unstructured":"Ferreyra Y, Rosas G, Cock-Rada AM, Araujo J, Bravo L, Doimi F, et al. Landscape of germline BRCA1\/BRCA2 variants in breast and ovarian cancer in Peru. Front Oncol. 2023; https:\/\/doi.org\/10.3389\/fonc.2023.1227864.","DOI":"10.3389\/fonc.2023.1227864"},{"key":"1807_CR4","doi-asserted-by":"publisher","unstructured":"Herzog JS, Chavarri-Guerra Y, Castillo D, Abugattas J, Villarreal-Garza C, Sand S, et al. Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America. NPJ Breast Cancer. 2021; https:\/\/doi.org\/10.1038\/s41523-021-00317-6.","DOI":"10.1038\/s41523-021-00317-6"},{"key":"1807_CR5","doi-asserted-by":"publisher","unstructured":"Ossa CA, Torres D Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review. Oncologist. 2016; https:\/\/doi.org\/10.1634\/theoncologist.2015-0416.","DOI":"10.1634\/theoncologist.2015-0416"},{"key":"1807_CR6","doi-asserted-by":"publisher","unstructured":"Torres D, Bermejo JL, Rashid MU, Briceno I, Gil F, Beltran A, et al. Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients. Sci Rep. 2017; https:\/\/doi.org\/10.1038\/s41598-017-05056-y.","DOI":"10.1038\/s41598-017-05056-y"},{"key":"1807_CR7","doi-asserted-by":"publisher","unstructured":"Cruz-Correa M, Perez-Mayoral J, Dutil J, Echenique M, Mosquera R, Rivera-Roman K, et al. Clinical Cancer Genetics Disparities among Latinos. J Genet Couns. 2017; https:\/\/doi.org\/10.1007\/s10897-016-0051-x.","DOI":"10.1007\/s10897-016-0051-x"},{"key":"1807_CR8","doi-asserted-by":"publisher","unstructured":"Sirugo G, Williams SM, Tishkoff SA The Missing Diversity in Human Genetic Studies. Cell. 2019; https:\/\/doi.org\/10.1016\/j.cell.2019.02.048.","DOI":"10.1016\/j.cell.2019.02.048"},{"key":"1807_CR9","doi-asserted-by":"publisher","unstructured":"Ossa H, Aquino J, Pereira R, Ibarra A, Ossa RH, Perez LA, et al. Outlining the Ancestry Landscape of Colombian Admixed Populations. PLoS One. 2016; https:\/\/doi.org\/10.1371\/journal.pone.0164414.","DOI":"10.1371\/journal.pone.0164414"},{"key":"1807_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ajpa.21270","author":"W Rojas","year":"2010","unstructured":"Rojas W, Parra MV, Campo O, Caro MA, Lopera JG, Arias W, et al. Genetic make up and structure of Colombian populations by means of uniparental and biparental DNA markers. Am J Phys Anthropol. 2010. https:\/\/doi.org\/10.1002\/ajpa.21270","journal-title":"Am J Phys Anthropol"},{"key":"1807_CR11","doi-asserted-by":"publisher","unstructured":"Sanabria-Salas MC, Hernandez-Suarez G, Umana-Perez A, Rawlik K, Tenesa A, Serrano-Lopez ML, et al. IL1B-CGTC haplotype is associated with colorectal cancer in admixed individuals with increased African ancestry. Sci Rep. 2017; https:\/\/doi.org\/10.1038\/srep41920.","DOI":"10.1038\/srep41920"},{"key":"1807_CR12","doi-asserted-by":"publisher","unstructured":"Bedoya G, Montoya P, Garcia J, Soto I, Bourgeois S, Carvajal L, et al. Admixture dynamics in Hispanics: a shift in the nuclear genetic ancestry of a South American population isolate. Proc Natl Acad Sci USA. 2006; https:\/\/doi.org\/10.1073\/pnas.0508716103.","DOI":"10.1073\/pnas.0508716103"},{"key":"1807_CR13","doi-asserted-by":"publisher","unstructured":"Carvajal-Carmona LG, Ophoff R, Service S, Hartiala J, Molina J, Leon P, et al. Genetic demography of Antioquia (Colombia) and the Central Valley of Costa Rica. Hum Genet. 2003; https:\/\/doi.org\/10.1007\/s00439-002-0899-8.","DOI":"10.1007\/s00439-002-0899-8"},{"key":"1807_CR14","doi-asserted-by":"publisher","unstructured":"Carvajal-Carmona LG, Soto ID, Pineda N, Ortiz-Barrientos D, Duque C, Ospina-Duque J, et al. Strong Amerind\/white sex bias and a possible Sephardic contribution among the founders of a population in northwest Colombia. Am J Hum Genet. 2000; https:\/\/doi.org\/10.1016\/S0002-9297(07)62956-5.","DOI":"10.1016\/S0002-9297(07)62956-5"},{"key":"1807_CR15","doi-asserted-by":"publisher","unstructured":"Criollo-Rayo AA, Bohorquez M, Prieto R, Howarth K, Culma C, Carracedo A, et al. Native American gene continuity to the modern admixed population from the Colombian Andes: Implication for biomedical, population and forensic studies. Forensic Sci Int Genet. 2018; https:\/\/doi.org\/10.1016\/j.fsigen.2018.06.006.","DOI":"10.1016\/j.fsigen.2018.06.006"},{"key":"1807_CR16","doi-asserted-by":"publisher","unstructured":"Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; https:\/\/doi.org\/10.6004\/jnccn.2021.0001.","DOI":"10.6004\/jnccn.2021.0001"},{"key":"1807_CR17","unstructured":"(INC). INdC. Anuario estad\u00edstico 2019. Bogot\u00e12021 2021."},{"key":"1807_CR18","unstructured":"(INC). INdC. Anuario estad\u00edstico 2020. Bogot\u00e1: INC; 2021."},{"key":"1807_CR19","doi-asserted-by":"publisher","unstructured":"Blair VR, McLeod M, Carneiro F, Coit DG, D\u2019Addario JL, van Dieren JM, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020; https:\/\/doi.org\/10.1016\/S1470-2045(20)30219-9.","DOI":"10.1016\/S1470-2045(20)30219-9"},{"key":"1807_CR20","doi-asserted-by":"publisher","unstructured":"Manotas MC, Rivera AL, Gomez AM, Abisambra P, Guevara G, Medina V, et al. SDHB exon 1 deletion: A recurrent germline mutation in Colombian patients with pheochromocytomas and paragangliomas. Front Genet. 2022; https:\/\/doi.org\/10.3389\/fgene.2022.999329.","DOI":"10.3389\/fgene.2022.999329"},{"key":"1807_CR21","doi-asserted-by":"publisher","unstructured":"Manotas MC, Rivera AL, Sanabria-Salas MC Variant curation and interpretation in hereditary cancer genes: An institutional experience in Latin America. Mol Genet Genomic Med. 2023; https:\/\/doi.org\/10.1002\/mgg3.2141.","DOI":"10.1002\/mgg3.2141"},{"key":"1807_CR22","doi-asserted-by":"publisher","unstructured":"Freeman PJ, Hart RK, Gretton LJ, Brookes AJ, Dalgleish R VariantValidator: Accurate validation, mapping, and formatting of sequence variation descriptions. Hum Mutat. 2018; https:\/\/doi.org\/10.1002\/humu.23348.","DOI":"10.1002\/humu.23348"},{"key":"1807_CR23","doi-asserted-by":"publisher","unstructured":"Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, et al. Cancer health disparities in racial\/ethnic minorities in the United States. Br J Cancer. 2021; https:\/\/doi.org\/10.1038\/s41416-020-01038-6.","DOI":"10.1038\/s41416-020-01038-6"},{"key":"1807_CR24","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; https:\/\/doi.org\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"1807_CR25","doi-asserted-by":"publisher","unstructured":"Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013; https:\/\/doi.org\/10.1245\/s10434-013-3205-1.","DOI":"10.1245\/s10434-013-3205-1"},{"key":"1807_CR26","doi-asserted-by":"publisher","unstructured":"Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Maehle L, Undlien DE, et al. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer. 2017; https:\/\/doi.org\/10.1186\/s12885-017-3422-2.","DOI":"10.1186\/s12885-017-3422-2"},{"key":"1807_CR27","doi-asserted-by":"publisher","unstructured":"Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 2018; https:\/\/doi.org\/10.1016\/j.cell.2018.03.039.","DOI":"10.1016\/j.cell.2018.03.039"},{"key":"1807_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-013-9693-0","author":"D Cuevas-Cuerda","year":"2014","unstructured":"Cuevas-Cuerda D, Salas-Trejo D. Evaluation after five years of the cancer genetic counselling programme of Valencian Community (Eastern Spain). Fam Cancer. 2014. https:\/\/doi.org\/10.1007\/s10689-013-9693-0.","journal-title":"Fam Cancer"},{"key":"1807_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-022-01098-7","author":"JM de Oliveira","year":"2022","unstructured":"de Oliveira JM, Zurro NB, Coelho AVC, Caraciolo MP, de Alexandre RB, Cervato MC, et al. The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients. Eur J Hum Genet. 2022. https:\/\/doi.org\/10.1038\/s41431-022-01098-7.","journal-title":"Eur J Hum Genet"},{"key":"1807_CR30","doi-asserted-by":"publisher","unstructured":"Perez-Ibave DC, Garza-Rodriguez ML, Noriega-Iriondo MF, Flores-Moreno SM, Gonzalez-Geroniz MI, Espinoza-Velazco A, et al. Identification of Germline Variants in Patients with Hereditary Cancer Syndromes in Northeast Mexico. Genes (Basel). 2023; https:\/\/doi.org\/10.3390\/genes14020341.","DOI":"10.3390\/genes14020341"},{"key":"1807_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-017-0004-z","author":"AM Cock-Rada","year":"2018","unstructured":"Cock-Rada AM, Ossa CA, Garcia HI, Gomez LR. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia. Fam Cancer. 2018. https:\/\/doi.org\/10.1007\/s10689-017-0004-z.","journal-title":"Fam Cancer"},{"key":"1807_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01429","author":"J Oliver","year":"2019","unstructured":"Oliver J, Quezada Urban R, Franco Cortes CA, Diaz Velasquez CE, Montealegre Paez AL, Pacheco-Orozco RA, et al. Latin American Study of Hereditary Breast and Ovarian Cancer LACAM: A Genomic Epidemiology Approach. Front Oncol. 2019. https:\/\/doi.org\/10.3389\/fonc.2019.01429","journal-title":"Front Oncol"},{"key":"1807_CR33","doi-asserted-by":"publisher","unstructured":"Ossa Gomez CA, Achatz MI, Hurtado M, Sanabria-Salas MC, Sullcahuaman Y, Chavarri-Guerra Y, et al. Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study. JCO Glob Oncol. 2022; https:\/\/doi.org\/10.1200\/GO.22.00104.","DOI":"10.1200\/GO.22.00104"},{"key":"1807_CR34","doi-asserted-by":"publisher","unstructured":"Sierra-Diaz DC, Morel A, Fonseca-Mendoza DJ, Bravo NC, Molano-Gonzalez N, Borras M, et al. Germline mutations of breast cancer susceptibility genes through expanded genetic analysis in unselected Colombian patients. Hum Genomics. 2024; https:\/\/doi.org\/10.1186\/s40246-024-00623-7.","DOI":"10.1186\/s40246-024-00623-7"},{"key":"1807_CR35","doi-asserted-by":"publisher","unstructured":"Serrano-Gomez SJ, Sanabria-Salas MC, Hernandez-Suarez G, Garcia O, Silva C, Romero A, et al. High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. Carcinogenesis. 2016; https:\/\/doi.org\/10.1093\/carcin\/bgw043.","DOI":"10.1093\/carcin\/bgw043"},{"key":"1807_CR36","doi-asserted-by":"publisher","unstructured":"Hu C, Polley EC, Yadav S, Lilyquist J, Shimelis H, Na J, et al. The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. J Natl Cancer Inst. 2020; https:\/\/doi.org\/10.1093\/jnci\/djaa023.","DOI":"10.1093\/jnci\/djaa023"},{"key":"1807_CR37","doi-asserted-by":"publisher","unstructured":"Sunga AY, Ricker C, Espenschied CR, Castillo D, Melas M, Herzog J, et al. Spectrum of mismatch repair gene mutations and clinical presentation of Hispanic individuals with Lynch syndrome. Cancer Genet. 2017; https:\/\/doi.org\/10.1016\/j.cancergen.2017.01.003.","DOI":"10.1016\/j.cancergen.2017.01.003"},{"key":"1807_CR38","doi-asserted-by":"publisher","unstructured":"Padua-Bracho A, Velazquez-Aragon JA, Fragoso-Ontiveros V, Nunez-Martinez PM, Mejia Aguayo ML, Sanchez-Contreras Y, et al. A Previously Unrecognized Molecular Landscape of Lynch Syndrome in the Mexican Population. Int J Mol Sci. 2022; https:\/\/doi.org\/10.3390\/ijms231911549.","DOI":"10.3390\/ijms231911549"},{"key":"1807_CR39","doi-asserted-by":"publisher","unstructured":"Alvarez K, Orellana P, De la Fuente M, Canales T, Pinto E, Heine C, et al. Spectrum and Frequency of Tumors, Cancer Risk and Survival in Chilean Families with Lynch Syndrome: Experience of the Implementation of a Registry. J Clin Med. 2020; https:\/\/doi.org\/10.3390\/jcm9061861.","DOI":"10.3390\/jcm9061861"},{"key":"1807_CR40","doi-asserted-by":"publisher","unstructured":"Della Valle A, Rossi BM, Palmero EI, Antelo M, Vaccaro CA, Lopez-Kostner F, et al. A snapshot of current genetic testing practice in Lynch syndrome: The results of a representative survey of 33 Latin American existing centres\/registries. Eur J Cancer. 2019; https:\/\/doi.org\/10.1016\/j.ejca.2019.07.017.","DOI":"10.1016\/j.ejca.2019.07.017"},{"key":"1807_CR41","doi-asserted-by":"publisher","unstructured":"Vaccaro CA, Lopez-Kostner F, Adriana DV, Palmero EI, Rossi BM, Antelo M, et al. From colorectal cancer pattern to the characterization of individuals at risk: Picture for genetic research in Latin America. Int J Cancer. 2019; https:\/\/doi.org\/10.1002\/ijc.31920.","DOI":"10.1002\/ijc.31920"},{"key":"1807_CR42","doi-asserted-by":"publisher","unstructured":"Rossi BM, Palmero EI, Lopez-Kostner F, Sarroca C, Vaccaro CA, Spirandelli F, et al. A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America. BMC Cancer. 2017; https:\/\/doi.org\/10.1186\/s12885-017-3599-4.","DOI":"10.1186\/s12885-017-3599-4"},{"key":"1807_CR43","doi-asserted-by":"publisher","unstructured":"Blay P, Santamaria I, Pitiot AS, Luque M, Alvarado MG, Lastra A, et al. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer. 2013; https:\/\/doi.org\/10.1186\/1471-2407-13-243.","DOI":"10.1186\/1471-2407-13-243"},{"key":"1807_CR44","doi-asserted-by":"publisher","unstructured":"Dutil J, Golubeva VA, Pacheco-Torres AL, Diaz-Zabala HJ, Matta JL, Monteiro AN The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. Breast Cancer Res Treat. 2015; https:\/\/doi.org\/10.1007\/s10549-015-3629-3.","DOI":"10.1007\/s10549-015-3629-3"},{"key":"1807_CR45","doi-asserted-by":"publisher","unstructured":"Esplin ED, Nielsen SM, Bristow SL, Garber JE, Hampel H, Rana HQ, et al. Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer. JCO Precis Oncol. 2022; https:\/\/doi.org\/10.1200\/PO.21.00516.","DOI":"10.1200\/PO.21.00516"},{"key":"1807_CR46","doi-asserted-by":"publisher","unstructured":"Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, et al. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. JAMA Oncol. 2021; https:\/\/doi.org\/10.1001\/jamaoncol.2020.6252.","DOI":"10.1001\/jamaoncol.2020.6252"},{"key":"1807_CR47","doi-asserted-by":"publisher","unstructured":"Kuzbari Z, Bandlamudi C, Loveday C, Garrett A, Mehine M, George A, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol. 2023; https:\/\/doi.org\/10.1016\/j.annonc.2022.12.003.","DOI":"10.1016\/j.annonc.2022.12.003"},{"key":"1807_CR48","doi-asserted-by":"publisher","unstructured":"Sanabria-Salas MC, Pedroza-Duran A, Diaz-Casas SE, Nunez Lemus M, Grillo-Ardila CF, Briceno-Morales X, et al. Management and Clinical Outcomes of Breast Cancer in Women Diagnosed with Hereditary Cancer Syndromes in a Clinic-Based Sample from Colombia. Cancers (Basel). 2024; https:\/\/doi.org\/10.3390\/cancers16112020.","DOI":"10.3390\/cancers16112020"},{"key":"1807_CR49","doi-asserted-by":"publisher","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; https:\/\/doi.org\/10.1038\/gim.2015.30.","DOI":"10.1038\/gim.2015.30"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01807-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01807-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01807-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T09:48:27Z","timestamp":1751536107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01807-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1807"],"URL":"https:\/\/doi.org\/10.1038\/s41431-025-01807-y","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Scientific Committee of the Instituto Nacional de Cancerolog\u00eda, Colombia (INC-C), approved the implementation of a Hereditary Cancer Program in 2017 as a Quality Improvement Project to provide germline genetic testing as a standard-of-care service for patients with cancer and suspected hereditary conditions. Participants in this institutional Program consented to donate biological samples to the National Tumor Biobank Terry Fox (BNTTF, in Spanish: Banco Nacional de Tumores Terry Fox), managed by the INC-C, and signed informed consent for DNA biobanking and future research studies. The Program\u2019s registry is being implemented for epidemiological reporting.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}